Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide available in the UK and other regions as a research chemical. It hasn’t been approved by the MHRA or any other health authorities for therapeutic use in humans. DSIP has been examined for various effects, though human clinical trials have shown mixed results, with much research based on animal studies:

• Sleep Regulation: DSIP is studied for its effect on sleep. Some research suggests it may promote deep, restorative sleep and reduce the time to fall asleep in those with disrupted sleep patterns. Unlike traditional sedatives, it appears to modulate sleep naturally without dependency.
• Stress and Anxiety Reduction: DSIP may help manage stress by regulating cortisol levels and promoting relaxation. Anxiolytic effects have been observed in animal models.
• Pain Management: Some studies hint that DSIP might have pain-relieving properties, possibly through interactions with opioid receptors, making it a candidate for chronic pain management.
• Hormonal Influence: DSIP has been linked to modulating hormones, including stimulating the release of luteinizing hormone and growth hormone, essential for recovery and well-being.
• Neuroprotection: Research is exploring DSIP’s potential to protect neurons from oxidative stress and its possible applications in neurodegenerative diseases like Alzheimer’s and Parkinson’s.
• Substance Withdrawal: Preliminary studies in humans suggest DSIP may help alleviate withdrawal symptoms from alcohol and opioids.

Note: BAC water is required for reconstitution.

• Administration: Subcutaneous injection.